Most recently, CRI has launched a new «venture philanthropy» program called the Cancer Vaccine Acceleration Fund (CVAF) as a means to catalyze development of next -
generation therapeutic cancer vaccines and other immunotherapies by helping to address the critical shortage of capital available for early stage clinical trials.